Heteromerization of G protein-coupled receptors: Relevance to neurological disorders and neurotherapeutics

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 5, 2010, Pages 636-650

  Albizu, Laura ^a   Moreno, José L ^a   González Maeso, Javier ^a   Sealfon, Stuart C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drug discovery; Gpcr; Heteromer; Heteromerization; Neurological disorder

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ALPHA ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 5; MU OPIATE RECEPTOR; OLIGOMER; SEROTONIN 2A RECEPTOR;

ADDICTION; ARTICLE; DRUG TARGETING; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; SCHIZOPHRENIA;

EID: 78649299930     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793361586     Document Type: Article

References (207)

1. Jordan, B.A.; Devi, L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature, 1999, 399, 697-700.
2. Ferre, S.; Baler, R.; Bouvier, M.; Caron, M.G.; Devi, L.A.; Durroux, T.; Fuxe, K.; George, S.R.; Javitch, J.A.; Lohse, M.J.; Mackie, K.; Milligan, G.; Pfleger, K.D.; Pin, J.P.; Volkow, N.D.; Waldhoer, M.; Woods, A.S.; Franco, R. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol., 2009, 5, 131-134.
3. Casado, V.; Cortes, A.; Mallol, J.; Perez-Capote, K.; Ferre, S.; Lluis, C.; Franco, R.; Canela, E.I. GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol. Ther., 2009, 124, 248-257.
4. Milligan, G.; Bouvier, M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J., 2005, 272, 2914-2925.
5. El-Asmar, L.; Springael, J.Y.; Ballet, S.; Andrieu, E.U.; Vassart, G.; Parmentier, M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol., 2005, 67, 460-469.
6. Springael, J.Y.; Le Minh, P.N.; Urizar, E.; Costagliola, S.; Vassart, G.; Parmentier, M. Allosteric modulation of binding properties between units of chemokine receptor homo-and hetero-oligomers. Mol. Pharmacol., 2006, 69, 1652-1661.
7. Pfleger, K.D.; Eidne, K.A. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat. Methods, 2006, 3, 165-174.
8. Franco, R.; Casado, V.; Cortes, A.; Mallol, J.; Ciruela, F.; Ferre, S.; Lluis, C.; Canela, E.I. G-protein-coupled receptor heteromers: function and ligand pharmacology. Br. J. Pharmacol., 2008, 153(Suppl 1), S90-S98.
9. Agnati, L.F.; Guidolin, D.; Leo, G.; Carone, C.; Genedani, S.; Fuxe, K. Receptor-receptor interactions: a novel concept in brain integration. Prog. Neurobiol., 2010, 90(2), 157-175.
10. Fuxe, K.; Canals, M.; Torvinen, M.; Marcellino, D.; Terasmaa, A.; Genedani, S.; Leo, G.; Guidolin, D.; Diaz-Cabiale, Z.; Rivera, A.; Lundstrom, L.; Langel, U.; Narvaez, J.; Tanganelli, S.; Lluis, C.; Ferre, S.; Woods, A.; Franco, R.; Agnati, L.F. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J. Neural Transm., 2007, 114, 49-75.
11. Fuxe, K.; Marcellino, D.; Rivera, A.; Diaz-Cabiale, Z.; Filip, M.; Gago, B.; Roberts, D.C.; Langel, U.; Genedani, S.; Ferraro, L.; de la Calle, A.; Narvaez, J.; Tanganelli, S.; Woods, A.; Agnati, L.F. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev., 2008, 58, 415-452.
12. Cottet, M.; Albizu, L.; Perkovska, S.; Jean-Alphonse, F.; Rahmeh, R.; Orcel, H.; Mejean, C.; Granier, S.; Mendre, C.; Mouillac, B.; Durroux, T. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. Curr. Opin. Pharmacol., 2009, 10(1), 59-66.
13. Albizu, L.; Balestre, M.N.; Breton, C.; Pin, J.P.; Manning, M.; Mouillac, B.; Barberis, C.; Durroux, T. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol. Pharmacol., 2006, 70, 1783-1791.
14. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci., 2001, 2, 274-286.
15. Mellado, M.; Rodriguez-Frade, J.M.; Vila-Coro, A.J.; Fernandez, S.; Martin de Ana, A.; Jones, D.R.; Toran, J.L.; Martinez, A.C. Chemokine receptor homoor heterodimerization activates distinct signaling pathways. EMBO J., 2001, 20, 2497-2507.
16. Filizola, M.; Olmea, O.; Weinstein, H. Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. Protein Eng., 2002, 15, 881-885.
17. Agnati, L.F.; Ferre, S.; Lluis, C.; Franco, R.; Fuxe, K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev., 2003, 55, 509-550.
18. Ciruela, F.; Burgueno, J.; Casado, V.; Canals, M.; Marcellino, D.; Goldberg, S.R.; Bader, M.; Fuxe, K.; Agnati, L.F.; Lluis, C.; Franco, R.; Ferre, S.; Woods, A.S. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem., 2004, 76, 5354-5363.
19. Terrillon, S.; Bouvier, M. Roles of G-protein-coupled receptor dimerization. EMBO Rep., 2004, 5, 30-34.
20. Wilson, S.; Wilkinson, G.; Milligan, G. The CXCR1 and CXCR2 receptors form constitutive homo-and heterodimers selectively and with equal apparent affinities. J. Biol. Chem., 2005, 280, 28663-28674.
21. Jordan, B.A.; Trapaidze, N.; Gomes, I.; Nivarthi, R.; Devi, L.A. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc. Natl. Acad. Sci. USA, 2001, 98, 343-348.
22. Pfeiffer, M.; Koch, T.; Schroder, H.; Laugsch, M.; Hollt, V.; Schulz, S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem., 2002, 277, 19762-19772.
23. Xu, J.; He, J.; Castleberry, A.M.; Balasubramanian, S.; Lau, A.G.; Hall, R.A. Heterodimerization of alpha 2A-and beta 1-adrenergic receptors. J. Biol. Chem., 2003, 278, 10770-10777.
24. Stanasila, L.; Perez, J.B.; Vogel, H.; Cotecchia, S. Oligomerization of the alpha 1a-and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J. Biol. Chem., 2003, 278, 40239-40251.
25. Lavoie, C.; Mercier, J.F.; Salahpour, A.; Umapathy, D.; Breit, A.; Villeneuve, L.R.; Zhu, W.Z.; Xiao, R.P.; Lakatta, E.G.; Bouvier, M.; Hebert, T.E. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem., 2002, 277, 35402-35410.
26. Breit, A.; Lagace, M.; Bouvier, M. Hetero-oligomerization between beta2-and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J. Biol. Chem., 2004, 279, 28756-28765.
27. Terrillon, S.; Barberis, C.; Bouvier, M. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc. Natl. Acad. Sci. USA, 2004, 101, 1548-1553.
28. Durroux, T. Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol. Sci., 2005, 26, 376-384.
29. Pfeiffer, M.; Koch, T.; Schroder, H.; Klutzny, M.; Kirscht, S.; Kreienkamp, H.J.; Hollt, V.; Schulz, S. Homo-and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem., 2001, 276, 14027-14036.
30. Urizar, E.; Montanelli, L.; Loy, T.; Bonomi, M.; Swillens, S.; Gales, C.; Bouvier, M.; Smits, G.; Vassart, G.; Costagliola, S. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J., 2005, 24, 1954-1964.
31. Zhu, W.Z.; Chakir, K.; Zhang, S.; Yang, D.; Lavoie, C.; Bouvier, M.; Hebert, T.E.; Lakatta, E.G.; Cheng, H.; Xiao, R.P. Heterodimerization of beta1-and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ. Res., 2005, 97, 244-255.
32. Jensen, A.A.; Spalding, T.A. Allosteric modulation of G-protein coupled receptors. Eur. J. Pharm. Sci, 2004, 21, 407-420.
33. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 198-210.
34. Rocheville, M.; Lange, D.C.; Kumar, U.; Patel, S.C.; Patel, R.C.; Patel, Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157.
35. AbdAlla, S.; Lother, H.; Quitterer, U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature, 2000, 407, 94-98.
36. Hague, C.; Lee, S.E.; Chen, Z.; Prinster, S.C.; Hall, R.A.; Minneman, K.P. Heterodimers of alpha1B-and alpha1D-adrenergic receptors form a single functional entity. Mol. Pharmacol., 2006, 69, 45-55.
37. Prinster, S.C.; Holmqvist, T.G.; Hall, R.A. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J. Pharmacol. Exp. Ther., 2006, 318, 974-981.
38. Levoye, A.; Dam, J.; Ayoub, M.A.; Guillaume, J.L.; Couturier, C.; Delagrange, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J., 2006, 25, 3012-3023.
39. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci., 2003, 24, 346-354.
40. George, S.R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B.F. Oligomerization of mu-and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem., 2000, 275, 26128-26135.
41. Rozenfeld, R.; Devi, L.A. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J., 2007, 21, 2455-2465.
42. Lee, S.P.; So, C.H.; Rashid, A.J.; Varghese, G.; Cheng, R.; Lanca, A.J.; O'Dowd, B.F.; George, S.R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 2004, 279, 35671-35678.
43. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA, 2007, 104, 654-659.
44. George, S.R.; O'Dowd, B.F.; Lee, S.P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 808-820.
45. Ferre, S.; Fredholm, B.B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 1997, 20, 482-487.
46. Fuxe, K.; Manger, P.; Genedani, S.; Agnati, L. The nigrostriatal DA pathway and Parkinson's disease. J. Neural Transm. Suppl., 2006, 71-83.
47. Foley, P.; Gerlach, M.; Double, K.L.; Riederer, P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm., 2004, 111, 1375-1446.
48. Kienast, T.; Heinz, A. Dopamine and the diseased brain. CNS Neurol. Disord. Drug Targets, 2006, 5, 109-131.
49. Hummel, M.; Unterwald, E.M. D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J. Cell Physiol., 2002, 191, 17-27.
50. Toda, S.; Alguacil, L.F.; Kalivas, P.W. Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J. Neurochem., 2003, 87, 1478-1484.
51. Angulo, E.; Casado, V.; Mallol, J.; Canela, E.I.; Vinals, F.; Ferrer, I.; Lluis, C.; Franco, R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol., 2003, 13, 440-451.
52. Ng, G.Y.; Mouillac, B.; George, S.R.; Caron, M.; Dennis, M.; Bouvier, M.; O'Dowd, B.F. Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur. J. Pharmacol., 1994, 267, 7-19.
53. Ciruela, F.; Casado, V.; Mallol, J.; Canela, E.I.; Lluis, C.; Franco, R. Immunological identification of A1 adenosine receptors in brain cortex. J. Neurosci. Res., 1995, 42, 818-828.
54. Ng, G.Y.; O'Dowd, B.F.; Lee, S.P.; Chung, H.T.; Brann, M.R.; Seeman, P.; George, S.R. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem. Biophys. Res. Commun., 1996, 227, 200-204.
55. Ciruela, F.; Casado, V.; Rodrigues, R.J.; Lujan, R.; Burgueno, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; Cortes, A.; Canela, E.I.; Lopez-Gimenez, J.F.; Milligan, G.; Lluis, C.; Cunha, R.A.; Ferre, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci., 2006, 26, 2080-2087.
56. So, C.H.; Varghese, G.; Curley, K.J.; Kong, M.M.; Alijaniaram, M.; Ji, X.; Nguyen, T.; O'Dowd B, F.; George, S.R. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol. Pharmacol., 2005, 68, 568-578.
57. Marcellino, D.; Ferre, S.; Casado, V.; Cortes, A.; Le Foll, B.; Mazzola, C.; Drago, F.; Saur, O.; Stark, H.; Soriano, A.; Barnes, C.; Goldberg, S.R.; Lluis, C.; Fuxe, K.; Franco, R. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem., 2008, 283, 26016-26025.
58. Fiorentini, C.; Busi, C.; Gorruso, E.; Gotti, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol., 2008, 74, 59-69.
59. Maggio, R.; Scarselli, M.; Novi, F.; Millan, M.J.; Corsini, G.U. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J. Neurochem., 2003, 87, 631-641.
60. Sokoloff, P.; Diaz, J.; Le Foll, B.; Guillin, O.; Leriche, L.; Bezard, E.; Gross, C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets, 2006, 5, 25-43.
61. Scarselli, M.; Novi, F.; Schallmach, E.; Lin, R.; Baragli, A.; Colzi, A.; Griffon, N.; Corsini, G.U.; Sokoloff, P.; Levenson, R.; Vogel, Z.; Maggio, R. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem., 2001, 276, 30308-30314.
62. Franco, R.; Ferre, S.; Agnati, L.; Torvinen, M.; Gines, S.; Hillion, J.; Casado, V.; Lledo, P.; Zoli, M.; Lluis, C.; Fuxe, K. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology, 2000, 23, S50-S59.
63. Hillion, J.; Canals, M.; Torvinen, M.; Casado, V.; Scott, R.; Terasmaa, A.; Hansson, A.; Watson, S.; Olah, M.E.; Mallol, J.; Canela, E.I.; Zoli, M.; Agnati, L.F.; Ibanez, C.F.; Lluis, C.; Franco, R.; Ferre, S.; Fuxe, K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem., 2002, 277, 18091-18097.
64. Torvinen, M.; Gines, S.; Hillion, J.; Latini, S.; Canals, M.; Ciruela, F.; Bordoni, F.; Staines, W.; Pedata, F.; Agnati, L.F.; Lluis, C.; Franco, R.; Ferre, S.; Fuxe, K. Interactions among adenosine deaminase, adenosine A(1) receptors and dopamine D(1) receptors in stably cotransfected fibroblast cells and neurons. Neuroscience, 2002, 113, 709-719.
65. Torvinen, M.; Kozell, L.B.; Neve, K.A.; Agnati, L.F.; Fuxe, K. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor. J. Mol. Neurosci., 2004, 24, 173-180.
66. Canals, M.; Marcellino, D.; Fanelli, F.; Ciruela, F.; de Benedetti, P.; Goldberg, S.R.; Neve, K.; Fuxe, K.; Agnati, L.F.; Woods, A.S.; Ferre, S.; Lluis, C.; Bouvier, M.; Franco, R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem., 2003, 278, 46741-46749.
67. Gines, S.; Hillion, J.; Torvinen, M.; Le Crom, S.; Casado, V.; Canela, E.I.; Rondin, S.; Lew, J.Y.; Watson, S.; Zoli, M.; Agnati, L.F.; Verniera, P.; Lluis, C.; Ferre, S.; Fuxe, K.; Franco, R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. USA, 2000, 97, 8606-8611.
68. Ferre, S.; Torvinen, M.; Antoniou, K.; Irenius, E.; Civelli, O.; Arenas, E.; Fredholm, B.B.; Fuxe, K. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J. Biol. Chem., 1998, 273, 4718-4724.
69. Cao, Y.; Xie, K.Q.; Zhu, X.Z. The enhancement of dopamine D1 receptor desensitization by adenosine A1 receptor activation. Eur. J. Pharmacol., 2007, 562, 34-38.
70. Le Crom, S.; Prou, D.; Vernier, P. Autocrine activation of adenosine A1 receptors blocks D1A but not D1B dopamine receptor desensitization. J. Neurochem., 2002, 82, 1549-1552.
71. Yabuuchi, K.; Kuroiwa, M.; Shuto, T.; Sotogaku, N.; Snyder, G.L.; Higashi, H.; Tanaka, M.; Greengard, P.; Nishi, A. Role of adenosine A1 receptors in the modulation of dopamine D1 and adenosine A2A receptor signaling in the neostriatum. Neuroscience, 2006, 141, 19-25.
72. Cao, Y.; Sun, W.C.; Jin, L.; Xie, K.Q.; Zhu, X.Z. Activation of adenosine A1 receptor modulates dopamine D1 receptor activity in stably cotransfected human embryonic kidney 293 cells. Eur. J. Pharmacol., 2006, 548, 29-35.
73. O'Neill, C.; Nolan, B.J.; Macari, A.; O'Boyle, K.M.; O'Connor, J.J. Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors. Eur. J. Neurosci., 2007, 26, 3421-3428.
74. Rivkees, S.A.; Price, S.L.; Zhou, F.C. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res., 1995, 677, 193-203.
75. Caille, I.; Dumartin, B.; Bloch, B. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res., 1996, 730, 17-31.
76. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA, 1991, 88, 7238-7241.
77. Ferre, S.; Fuxe, K. Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res., 1992, 594, 124-130.
78. Fuxe, K.; Ferre, S.; Canals, M.; Torvinen, M.; Terasmaa, A.; Marcellino, D.; Goldberg, S.R.; Staines, W.; Jacobsen, K.X.; Lluis, C.; Woods, A.S.; Agnati, L.F.; Franco, R. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci., 2005, 26, 209-220.
79. Kamiya, T.; Saitoh, O.; Yoshioka, K.; Nakata, H. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem. Biophys. Res. Commun., 2003, 306, 544-549.
80. Navarro, G.; Aymerich, M.S.; Marcellino, D.; Cortes, A.; Casado, V.; Mallol, J.; Canela, E.I.; Agnati, L.; Woods, A.S.; Fuxe, K.; Lluis, C.; Lanciego, J.L.; Ferre, S.; Franco, R. Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors. J. Biol. Chem., 2009, 284, 28058-28068.
81. Ferre, S.; Ciruela, F.; Canals, M.; Marcellino, D.; Burgueno, J.; Casado, V.; Hillion, J.; Torvinen, M.; Fanelli, F.; Benedetti Pd, P.; Goldberg, S.R.; Bouvier, M.; Fuxe, K.; Agnati, L.F.; Lluis, C.; Franco, R.; Woods, A. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord., 2004, 10, 265-271.
82. Ferre, S.; Quiroz, C.; Woods, A.S.; Cunha, R.; Popoli, P.; Ciruela, F.; Lluis, C.; Franco, R.; Azdad, K.; Schiffmann, S.N. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des., 2008, 14, 1468-1474.
83. Fuxe, K.; Agnati, L.F.; Jacobsen, K.; Hillion, J.; Canals, M.; Torvinen, M.; Tinner-Staines, B.; Staines, W.; Rosin, D.; Terasmaa, A.; Popoli, P.; Leo, G.; Vergoni, V.; Lluis, C.; Ciruela, F.; Franco, R.; Ferre, S. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology, 2003, 61, S19-S23.
84. Marcellino, D.; Roberts, D.C.; Navarro, G.; Filip, M.; Agnati, L.; Lluis, C.; Franco, R.; Fuxe, K. Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. Brain Res., 2007, 1143, 208-220.
85. Kanda, T.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol., 1998, 43, 507-513.
86. Ferre, S.; Popoli, P.; Gimenez-Llort, L.; Rimondini, R.; Muller, C.E.; Stromberg, I.; Ogren, S.O.; Fuxe, K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord., 2001, 7, 235-241.
87. Rimondini, R.; Ferre, S.; Ogren, S.O.; Fuxe, K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology, 1997, 17, 82-91.
88. Bara-Jimenez, W.; Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris, M.J.; Mouradian, M.M.; Chase, T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology, 2003, 61, 293-296.
89. Pinna, A.; Wardas, J.; Simola, N.; Morelli, M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci., 2005, 77, 3259-3267.
90. Simola, N.; Morelli, M.; Pinna, A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr. Pharm. Des., 2008, 14, 1475-1489.
91. Carta, A.R.; Kachroo, A.; Schintu, N.; Xu, K.; Schwarzschild, M.A.; Wardas, J.; Morelli, M. Inactivation of neuronal forebrain A(2A) receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem., 2009, 111(6), 1478-1489.
92. Ferre, S.; O'Connor, W.T.; Snaprud, P.; Ungerstedt, U.; Fuxe, K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience, 1994, 63, 765-773.
93. Akhondzadeh, S.; Shasavand, E.; Jamilian, H.; Shabestari, O.; Kamalipour, A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther., 2000, 25, 131-137.
94. Ferre, S.; Karcz-Kubicha, M.; Hope, B.T.; Popoli, P.; Burgueno, J.; Gutierrez, M.A.; Casado, V.; Fuxe, K.; Goldberg, S.R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA, 2002, 99, 11940-11945.
95. Domenici, M.R.; Pepponi, R.; Martire, A.; Tebano, M.T.; Potenza, R.L.; Popoli, P. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J. Neurochem., 2004, 90, 1276-1279.
96. Rodrigues, R.J.; Alfaro, T.M.; Rebola, N.; Oliveira, C.R.; Cunha, R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem., 2005, 92, 433-441.
97. Ferre, S.; Popoli, P.; Rimondini, R.; Reggio, R.; Kehr, J.; Fuxe, K. Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology, 1999, 38, 129-140.
98. Popoli, P.; Pezzola, A.; Torvinen, M.; Reggio, R.; Pintor, A.; Scarchilli, L.; Fuxe, K.; Ferre, S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology, 2001, 25, 505-513.
99. Diaz-Cabiale, Z.; Vivo, M.; Del Arco, A.; O'Connor, W.T.; Harte, M.K.; Muller, C.E.; Martinez, E.; Popoli, P.; Fuxe, K.; Ferre, S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett., 2002, 324, 154-158.
100. Coccurello, R.; Breysse, N.; Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology, 2004, 29, 1451-1461.
101. Kachroo, A.; Orlando, L.R.; Grandy, D.K.; Chen, J.F.; Young, A.B.; Schwarzschild, M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci., 2005, 25, 10414-10419.
102. Cabello, N.; Gandia, J.; Bertarelli, D.C.; Watanabe, M.; Lluis, C.; Franco, R.; Ferre, S.; Lujan, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem., 2009, 109, 1497-1507.
103. Nishi, A.; Liu, F.; Matsuyama, S.; Hamada, M.; Higashi, H.; Nairn, A.C.; Greengard, P. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. USA, 2003, 100, 1322-1327.
104. Marino, M.J.; Valenti, O.; Conn, P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging, 2003, 20, 377-397.
105. Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105, 267-310.
106. Adams, C.L.; Cowen, M.S.; Short, J.L.; Lawrence, A.J. Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats. Int. J. Neuropsychopharmacol., 2008, 11, 229-241.
107. Pickel, V.M.; Chan, J.; Kearn, C.S.; Mackie, K. Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J. Comp. Neurol., 2006, 495, 299-313.
108. Yin, H.H.; Lovinger, D.M. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. USA, 2006, 103, 8251-8256.
109. Julian, M.D.; Martin, A.B.; Cuellar, B.; Rodriguez De Fonseca, F.; Navarro, M.; Moratalla, R.; Garcia-Segura, L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience, 2003, 119, 309-318.
110. Fusco, F.R.; Martorana, A.; Giampa, C.; De March, Z.; Farini, D.; D'Angelo, V.; Sancesario, G.; Bernardi, G. Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. Synapse, 2004, 53, 159-167.
111. Kofalvi, A.; Rodrigues, R.J.; Ledent, C.; Mackie, K.; Vizi, E.S.; Cunha, R.A.; Sperlagh, B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci., 2005, 25, 2874-2884.
112. Matyas, F.; Yanovsky, Y.; Mackie, K.; Kelsch, W.; Misgeld, U.; Freund, T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience, 2006, 137, 337-361.
113. Tebano, M.T.; Martire, A.; Chiodi, V.; Pepponi, R.; Ferrante, A.; Domenici, M.R.; Frank, C.; Chen, J.F.; Ledent, C.; Popoli, P. Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J. Neurochem., 2009, 110, 1921-1930.
114. Carriba, P.; Ortiz, O.; Patkar, K.; Justinova, Z.; Stroik, J.; Themann, A.; Muller, C.; Woods, A.S.; Hope, B.T.; Ciruela, F.; Casado, V.; Canela, E.I.; Lluis, C.; Goldberg, S.R.; Moratalla, R.; Franco, R.; Ferre, S. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology, 2007, 32, 2249-2259.
115. Soria, G.; Castane, A.; Berrendero, F.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur. J. Neurosci., 2004, 20, 2203-2213.
116. Meschler, J.P.; Howlett, A.C. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology, 2001, 40, 918-926.
117. Jarrahian, A.; Watts, V.J.; Barker, E.L. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther., 2004, 308, 880-886.
118. Martin, A.B.; Fernandez-Espejo, E.; Ferrer, B.; Gorriti, M.A.; Bilbao, A.; Navarro, M.; Rodriguez de Fonseca, F.; Moratalla, R. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology, 2008, 33, 1667-1679.
119. Martin, M.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl.), 2002, 159, 379-387.
120. Ledent, C.; Valverde, O.; Cossu, G.; Petitet, F.; Aubert, J.F.; Beslot, F.; Bohme, G.A.; Imperato, A.; Pedrazzini, T.; Roques, B.P.; Vassart, G.; Fratta, W.; Parmentier, M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 1999, 283, 401-404.
121. Yao, L.; McFarland, K.; Fan, P.; Jiang, Z.; Ueda, T.; Diamond, I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl. Acad. Sci. USA, 2006, 103, 7877-7882.
122. Alen, F.; Moreno-Sanz, G.; Isabel de Tena, A.; Brooks, R.D.; Lopez-Jimenez, A.; Navarro, M.; Lopez-Moreno, J.A. Pharmacological activation of CB1 and D2 receptors in rats: predominant role of CB1 in the increase of alcohol relapse. Eur. J. Neurosci., 2008, 27, 3292-3298.
123. Rasmussen, B.A.; Kim, E.; Unterwald, E.M.; Rawls, S.M. Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB(1)-dopamine D(2) receptor mechanism. Brain Res., 2009, [Epub ahead of print].
124. Kearn, C.S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol., 2005, 67, 1697-1704.
125. Marcellino, D.; Carriba, P.; Filip, M.; Borgkvist, A.; Frankowska, M.; Bellido, I.; Tanganelli, S.; Muller, C.E.; Fisone, G.; Lluis, C.; Agnati, L.F.; Franco, R.; Fuxe, K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology, 2008, 54, 815-823.
126. Ferre, S.; Goldberg, S.R.; Lluis, C.; Franco, R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology, 2009, 56(Suppl 1), 226-234.
127. Navarro, G.; Carriba, P.; Gandia, J.; Ciruela, F.; Casado, V.; Cortes, A.; Mallol, J.; Canela, E.I.; Lluis, C.; Franco, R. Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Sci. World J., 2008, 8, 1088-1097.
128. Carriba, P.; Navarro, G.; Ciruela, F.; Ferre, S.; Casado, V.; Agnati, L.; Cortes, A.; Mallol, J.; Fuxe, K.; Canela, E.I.; Lluis, C.; Franco, R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods, 2008, 5, 727-733.
129. Kerppola, T.K. Bimolecular fluorescence complementation: visualization of molecular interactions in living cells. Methods Cell Biol., 2008, 85, 431-470.
130. Deckert, J.; Brenner, M.; Durany, N.; Zochling, R.; Paulus, W.; Ransmayr, G.; Tatschner, T.; Danielczyk, W.; Jellinger, K.; Riederer, P. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport, 2003, 14, 313-316.
131. Guillin, O.; Abi-Dargham, A.; Laruelle, M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol., 2007, 78, 1-39.
132. Dean, B.; Sundram, S.; Bradbury, R.; Scarr, E.; Copolov, D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 2001, 103, 9-15.
133. Sundram, S.; Copolov, D.; Dean, B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch. Pharmacol., 2005, 371, 428-433.
134. Uriguen, L.; Garcia-Fuster, M.J.; Callado, L.F.; Morentin, B.; La Harpe, R.; Casado, V.; Lluis, C.; Franco, R.; Garcia-Sevilla, J.A.; Meana, J.J. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl.), 2009, 206, 313-324.
135. Nichols, D.E.; Nichols, C.D. Serotonin receptors. Chem. Rev., 2008, 108, 1614-1641.
136. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; Lopez-Gimenez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.
137. Gonzalez-Maeso, J.; Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci., 2009, 32, 225-232.
138. Gonzalez-Maeso, J.; Sealfon, S.C. Agonist-trafficking and hallucinogens. Curr. Med. Chem., 2009, 16, 1017-1027.
139. Moreno, J.L.; Sealfon, S.C.; Gonzalez-Maeso, J. Group II metabotropic glutamate receptors and schizophrenia. Cell Mol. Life Sci., 2009, 66, 3777-3785.
140. Sealfon, S.C.; Gonzalez-Maeso, J. Receptor pair for schizophrenia. Pediatr. Res., 2008, 64, 1.
141. Gonzalez-Maeso, J.; Yuen, T.; Ebersole, B.J.; Wurmbach, E.; Lira, A.; Zhou, M.; Weisstaub, N.; Hen, R.; Gingrich, J.A.; Sealfon, S.C. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J. Neurosci., 2003, 23, 8836-8843.
142. Gonzalez-Maeso, J.; Weisstaub, N.V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A.; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; Sealfon, S.C.; Gingrich, J.A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron, 2007, 53, 439-452.
143. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med., 2007, 13, 1102-1107.
144. Aghajanian, G.K.; Marek, G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev., 2000, 31, 302-312.
145. Marek, G.J. Metabotropic glutamate 2/3 receptors as drug targets. Curr. Opin. Pharmacol., 2004, 4, 18-22.
146. Morita, K.; North, R.A. Clonidine activates membrane potassium conductance in myenteric neurones. Br. J. Pharmacol., 1981, 74, 419-428.
147. Richman, J.G.; Regan, J.W. Alpha 2-adrenergic receptors increase cell migration and decrease F-actin labeling in rat aortic smooth muscle cells. Am. J. Physiol., 1998, 274, C654-662.
148. Jordan, B.; Devi, L.A. Molecular mechanisms of opioid receptor signal transduction. Br. J. Anaesth., 1998, 81, 12-19.
149. Macdonald, R.L.; Nelson, P.G. Specific-opiate-induced depression of transmitter release from dorsal root ganglion cells in culture. Science, 1978, 199, 1449-1451.
150. Stone, L.S.; MacMillan, L.B.; Kitto, K.F.; Limbird, L.E.; Wilcox, G.L. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J. Neurosci., 1997, 17, 7157-7165.
151. Wigdor, S.; Wilcox, G.L. Central and systemic morphine-induced antinociception in mice: contribution of descending serotonergic and noradrenergic pathways. J. Pharmacol. Exp. Ther., 1987, 242, 90-95.
152. Matthes, H.W.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K.; Dierich, A.; Le Meur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B.P.; Kieffer, B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature, 1996, 383, 819-823.
153. Glass, M.J.; Pickel, V.M. Alpha(2A)-adrenergic receptors are present in mu-opioid receptor containing neurons in rat medial nucleus tractus solitarius. Synapse, 2002, 43, 208-218.
154. Jordan, B.A.; Gomes, I.; Rios, C.; Filipovska, J.; Devi, L.A. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol. Pharmacol., 2003, 64, 1317-1324.
155. Zhang, Y.Q.; Limbird, L.E. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem. Soc. Trans., 2004, 32, 856-860.
156. Vilardaga, J.P.; Nikolaev, V.O.; Lorenz, K.; Ferrandon, S.; Zhuang, Z.; Lohse, M.J. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol., 2008, 4, 126-131.
157. Spaulding, T.C.; Fielding, S.; Venafro, J.J.; Lal, H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur. J. Pharmacol., 1979, 58, 19-25.
158. Wilcox, G.L.; Carlsson, K.H.; Jochim, A.; Jurna, I. Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord. Brain Res., 1987, 405, 84-93.
159. Tan, M.; Walwyn, W.M.; Evans, C.J.; Xie, C.W. p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons. J. Biol. Chem., 2009, 284, 6270-6281.
160. Ulibarri, I.; Garcia-Sevilla, J.A.; Ugedo, L. Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats. Naunyn Schmiedebergs Arch. Pharmacol., 1987, 336, 530-537.
161. Smith, C.B.; Moises, H.C.; Spengler, R.N.; Hollingsworth, P.J. Changes in alpha 2-adrenoceptor number and function in brains of morphine-dependent rats. Eur. J. Pharmacol., 1989, 161, 111-119.
162. Gabilondo, A.M.; Meana, J.J.; Barturen, F.; Sastre, M.; GarciaSevilla, J.A. Mu-Opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology (Berl.), 1994, 115, 135-140.
163. Meana, J.J.; Gonzalez-Maeso, J.; Garcia-Sevilla, J.A.; Guimon, J. mu-opioid receptor and alpha2-adrenoceptor agonist stimulation of [35S]GTPgammaS binding to G-proteins in postmortem brains of opioid addicts. Mol. Psychiatry, 2000, 5, 308-315.
164. Ciruela, F.; Escriche, M.; Burgueno, J.; Angulo, E.; Casado, V.; Soloviev, M.M.; Canela, E.I.; Mallol, J.; Chan, W.Y.; Lluis, C.; McIlhinney, R.A.; Franco, R. Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J. Biol. Chem., 2001, 276, 18345-18351.
165. Stutzmann, G.E.; Marek, G.J.; Aghajanian, G.K. Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience, 2001, 105, 55-69.
166. Marek, G.J. Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. Neuropharmacology, 2009, 56, 1082-1087.
167. Ferrada, C.; Ferre, S.; Casado, V.; Cortes, A.; Justinova, Z.; Barnes, C.; Canela, E.I.; Goldberg, S.R.; Leurs, R.; Lluis, C.; Franco, R. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology, 2008, 55, 190-197.
168. Mikhailova, M.V.; Mayeux, P.R.; Jurkevich, A.; Kuenzel, W.J.; Madison, F.; Periasamy, A.; Chen, Y.; Cornett, L.E. Heterooligomerization between vasotocin and corticotropin-releasing hormone (CRH) receptors augments CRH-stimulated 3',5'-cyclic adenosine monophosphate production. Mol. Endocrinol., 2007, 21, 2178-2188.
169. Young, S.F.; Griffante, C.; Aguilera, G. Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors. Cell Mol. Neurobiol., 2007, 27, 439-461.
170. Mikhailova, M.V.; Blansett, J.; Jacobi, S.; Mayeux, P.R.; Cornett, L.E. Transmembrane domain IV of the Gallus gallus VT2 vasotocin receptor is essential for forming a heterodimer with the corticotrophin releasing hormone receptor. J. Biomed. Opt., 2008, 13, 031208.
171. Milligan, G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov. Today, 2006, 11, 541-549.
172. Kent, T.; McAlpine, C.; Sabetnia, S.; Presland, J. G-protein-coupled receptor heterodimerization: assay technologies to clinical significance. Curr. Opin. Drug Discov. Devel., 2007, 10, 580-589.
173. Dalrymple, M.B.; Pfleger, K.D.; Eidne, K.A. G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol. Ther., 2008, 118, 359-371.
174. Waldhoer, M.; Fong, J.; Jones, R.M.; Lunzer, M.M.; Sharma, S.K.; Kostenis, E.; Portoghese, P.S.; Whistler, J.L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. USA, 2005, 102, 9050-9055.
175. Daniels, D.J.; Lenard, N.R.; Etienne, C.L.; Law, P.Y.; Roerig, S.C.; Portoghese, P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA, 2005, 102, 19208-19213.
176. Xie, Z.; Bhushan, R.G.; Daniels, D.J.; Portoghese, P.S. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol., 2005, 68, 1079-1086.
177. Breit, A.; Gagnidze, K.; Devi, L.A.; Lagace, M.; Bouvier, M. Simultaneous activation of the delta opioid receptor (deltaOR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits deltaOR signaling. Mol. Pharmacol., 2006, 70, 686-696.
178. Zhang, Z.J.; Jiang, X.L.; Zhang, S.E.; Hough, C.J.; Li, H.; Chen, J.G.; Zhen, X.C. The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm. Neurosci. Lett., 2005, 382, 134-138.
179. Natesan, S.; Reckless, G.E.; Barlow, K.B.; Odontiadis, J.; Nobrega, J.N.; Baker, G.B.; George, S.R.; Mamo, D.; Kapur, S. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl.), 2008, 199, 275-289.
180. Liu, Z.; Zhang, J.; Zhang, A. Design of multivalent ligand targeting G-protein-coupled receptors. Curr. Pharm. Des., 2009, 15, 682-718.
181. Zhang, A.; Liu, Z.; Kan, Y. Receptor dimerization--rationale for the design of bivalent ligands. Curr. Top. Med. Chem., 2007, 7, 343-345.
182. Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casado, V.; Cortes, A.; Fanelli, F.; Albericio, F.; Lluis, C.; Franco, R.; Royo, M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem., 2009, 52, 5590-5602.
183. Springael, J.Y.; Urizar, E.; Costagliola, S.; Vassart, G.; Parmentier, M. Allosteric properties of G protein-coupled receptor oligomers. Pharmacol. Ther., 2007, 115, 410-418.
184. Gurevich, V.V.; Gurevich, E.V. GPCR monomers and oligomers: it takes all kinds. Trends Neurosci., 2008, 31, 74-81.
185. Rives, M.L.; Vol, C.; Fukazawa, Y.; Tinel, N.; Trinquet, E.; Ayoub, M.A.; Shigemoto, R.; Pin, J.P.; Prezeau, L. Crosstalk between GABA(B) and mGlu1a receptors reveals new insight into GPCR signal integration. EMBO J., 2009, 28, 2195-2208.
186. Damak, S.; Rong, M.; Yasumatsu, K.; Kokrashvili, Z.; Varadarajan, V.; Zou, S.; Jiang, P.; Ninomiya, Y.; Margolskee, R.F. Detection of sweet and umami taste in the absence of taste receptor T1r3. Science, 2003, 301, 850-853.
187. Zhao, G.Q.; Zhang, Y.; Hoon, M.A.; Chandrashekar, J.; Erlenbach, I.; Ryba, N.J.; Zuker, C.S. The receptors for mammalian sweet and umami taste. Cell, 2003, 115, 255-266.
188. Gomes, I.; Jordan, B.A.; Gupta, A.; Trapaidze, N.; Nagy, V.; Devi, L.A. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J. Neurosci., 2000, 20, RC110.
189. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H.H.; Pintar, J.E.; Devi, L.A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. USA, 2004, 101, 5135-5139.
190. Barki-Harrington, L.; Luttrell, L.M.; Rockman, H.A. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation, 2003, 108, 1611-1618.
191. Deighan, C.; Methven, L.; Naghadeh, M.M.; Wokoma, A.; Macmillan, J.; Daly, C.J.; Tanoue, A.; Tsujimoto, G.; McGrath, J.C. Insights into the functional roles of alpha(1)-adrenoceptor subtypes in mouse carotid arteries using knockout mice. Br. J. Pharmacol., 2005, 144, 558-565.
192. Mattera, R.; Pitts, B.J.; Entman, M.L.; Birnbaumer, L. Guanine nucleotide regulation of a mammalian myocardial muscarinic receptor system. Evidence for homo-and heterotropic cooperativity in ligand binding analyzed by computer-assisted curve fitting. J. Biol. Chem., 1985, 260, 7410-7421.
193. Wreggett, K.A.; Wells, J.W. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J. Biol. Chem., 1995, 270, 22488-22499.
194. Pontier, S.M.; Percherancier, Y.; Galandrin, S.; Breit, A.; Gales, C.; Bouvier, M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J. Biol. Chem., 2008, 283, 24659-24672.
195. Orcel, H.; Albizu, L.; Perkovska, S.; Durroux, T.; Mendre, C.; Ansanay, H.; Mouillac, B.; Rabie, A. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. Mol. Pharmacol., 2009, 75, 637-647.
196. Razani, B.; Woodman, S.E.; Lisanti, M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev., 2002, 54, 431-467.
197. Albizu, L.; Teppaz, G.; Seyer, R.; Bazin, H.; Ansanay, H.; Manning, M.; Mouillac, B.; Durroux, T. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J. Med. Chem., 2007, 50, 4976-4985.
198. Albizu, L.; Cottet, M.; Stoev, S.; Seyer, R.; Brabet, I.; Roux, T.; Bazin, H.; Bourrier, E.; Lamarque, L.; Breton, C.; Rives, M-L.; Kralikova, M.; Newman A.H.; Javitch, J.A.; Trinquet, E.; Manning, M.; Pin, J-P.; Mouillac, B.; Durroux, T. Time-resolved FRET between ligands bound on asymmetric G protein-coupled receptors reveals oligomers in native tissues. Nat. Chem. Biol., 2010, in press.
199. Zoli, M.; Agnati, L.F.; Hedlund, P.B.; Li, X.M.; Ferre, S.; Fuxe, K. Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol., 1993, 7, 293-334.
200. Agnati, L.F.; Franzen, O.; Ferre, S.; Leo, G.; Franco, R.; Fuxe, K. Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J. Neural Transm. Suppl., 2003, 1-28.
201. Pin, J.P.; Neubig, R.; Bouvier, M.; Devi, L.; Filizola, M.; Javitch, J.A.; Lohse, M.J.; Milligan, G.; Palczewski, K.; Parmentier, M.; Spedding, M. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev., 2007, 59, 5-13.
202. Lopez-Gimenez, J.F.; Canals, M.; Pediani, J.D.; Milligan, G. The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Mol. Pharmacol., 2007, 71, 1015-1029.
203. Guo, W.; Urizar, E.; Kralikova, M.; Mobarec, J.C.; Shi, L.; Filizola, M.; Javitch, J.A. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J., 2008, 27, 2293-2304.
204. Pin, J.P.; Comps-Agrar, L.; Maurel, D.; Monnier, C.; Rives, M.L.; Trinquet, E.; Kniazeff, J.; Rondard, P.; Prezeau, L. G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABA(B) receptors. J. Physiol., 2009, 587, 5337-5344.
205. Maurel, D.; Comps-Agrar, L.; Brock, C.; Rives, M.L.; Bourrier, E.; Ayoub, M.A.; Bazin, H.; Tinel, N.; Durroux, T.; Prezeau, L.; Trinquet, E.; Pin, J.P. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat. Methods, 2008, 5, 561-567.
206. Bockaert, J.; Dumuis, A.; Fagni, L.; Marin, P. GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr. Opin. Drug Discov. Devel., 2004, 7, 649-657.
207. Kabbani, N.; Levenson, R. A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex. Eur. J. Pharmacol., 2007, 572, 83-93.